

Special Issue

Vaccination Advances for HBV, HPV, and Influenza

Message from the Guest Editor

Hepatitis B leads to chronic liver disease and cancer, causing approximately 1.1 million deaths annually. Human papillomavirus (HPV) is responsible for almost all cases of cervical cancer and other malignancies, resulting in over 300,000 deaths each year. With its seasonal and pandemic potential, influenza affects millions globally, leading to substantial morbidity and mortality. Vaccines for these diseases have shown effectiveness: HBV and HPV vaccines offer 90-100% against cancer-causing strains, and influenza vaccines reduce illness and death. High vaccination coverage prevents individual infections and promotes herd immunity. This Special Issue welcomes submissions including but not restricted to the following:

- Progress in HBV, HPV, or influenza vaccination among vulnerable subpopulations (e.g., infants, children, elderly, health care workers, etc);
- Integrated vaccination programs;
- Different vaccination strategies for HBV, HPV, or influenza across regions, particularly new vaccine technologies.

Guest Editor

Dr. Wangnan Cao

Department of Social Medicine and Health Education, School of Public Health, Peking University Health Science Center, Beijing 100191, China

Deadline for manuscript submissions

31 August 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/210691

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).